MIRA Pharmaceuticals initiates Phase 2a study of Ketamir-2 for chemotherapy-induced peripheral neuropathy, targeting an undertreated condition affecting over ha
PEDMARK hearing protection met its primary endpoint in a Phase 2 study, showing significant ototoxicity reduction without compromising cisplatin's...
Mayo Test Drive completed at 97.5% across MCI, mild, and moderate dementia patients, here's what that means for Alzheimer's...
Medpace expands Phase I Unit with on-site imaging and specialized assessments to reduce participant dropout and keep trial endpoints...
Risk-based quality management requires linking quality plans to data management protocols. EU regulators now expect documented traceability between RBQM...
Coya Therapeutics enrolls 100th patient in ALSTARS trial of COYA 302 for ALS, reaching a key recruitment milestone for...
BH-30643 achieves 45% response rate in osimertinib-resistant NSCLC patients with C797S mutations, showing 88% disease control in Phase 1/2...
Summit Therapeutics presents updated overall survival results for ivonescimab in EGFR-mutated NSCLC from the Phase III HARMONi trial.
Roche's Lunsumio combo met its primary endpoint in Phase III follicular lymphoma trial, beating rituximab plus lenalidomide on progression-free...
